Skip to content

Effect of Mughat(Unani single drug) in disease of skeletal muscle weakness

Efficacy of Moghat in Sarcopenia among elderly; A randomized placebo-controlled study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072106
Enrollment
42
Registered
2024-08-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M628- Other specified disorders of muscle

Interventions

Intervention1: Mughat: The drug will be identified in crude form. The drug will be cleaned to remove any unwanted material and impurities and then powdered. 7gram coarsely powdered drug has to be soak

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age less than and equal to 60 years 2 Grip Strength in Men less than 27 and in Women less than 16 3 Gait Speed less than and equal to 0.8 meter per second 4 Time up and go test(time needed to rise from seated and walk 3 meter away and back with return to seated) less than 20 seconds 5 SPPB(short physical performance Battery) less than 8 points A Standing Balance a)Side by side stand feet in parallel paired position for 10 sec b)Semi tandem stand feet in parallel non paired position for 10 sec c Tandem stand test (put one foot Infront of other) B 4meter walking speed C Chair stand test [Total SPPB Score will be obtain by adding the scores of standing balance test, gait speed test and chair stands test]

Exclusion criteria

Exclusion criteria: 1 Age younger than 60 years 2 Protein-calorie malabsorption(Celiac disease,Crohn’s disease,Tropical sprue, Whipple’s disease,Chronic pancreatitis,cystic fibrosis,Biliary cirrhosis,primary sclerosing cholangitis,Intestinal tuberculosis,Intestinal lymphangiectasia,Intestinal lymphoma) 3 Presence of morbidity(uncontrolled hypertension,and type 2 Diabetes Mellitus, neurologic disorders,metabolic diseases, rheumatic diseases,heart failure,severe chronic obstructive pulmonary disease (COPD), hemocoagulation syndromes, terminal cancer, severe renal diseases, Poor Controlled psychiatric disease such as schizophrenia, and blindness) 4 Use of medication(immunosuppressive drugs, insulin) 5 Immobilization for 1 week during the last 3 months, Patients with acute immobility(i.e. post hip fracture or post-acute hospital admission) should be excluded, orthopedic surgery during the last 2 years or still causing pain or functional limitation 6 Highly trained athletes were excluded

Design outcomes

Primary

MeasureTime frame
improvement in muscle strength by using Grip Strength,Gait Speed,Time up and go test,SPPB (short physical performance Battery)Timepoint: at Baseline, 30th day , 60th day

Secondary

MeasureTime frame
Assessment of Efficacy 1.Upper arm circumference 2.Calf circumference 3.Thigh circumference 4.Grip strength 5.Body weight 6.Timed & climbs of flight of stairs (4 to 11) 7.Skin fold thickness 8.Gait speed 9.Time up & go test 10. 6 MWD(6 minute walk distance) 11.30 second chair stand test 12.Range of motion 13.Complete hemogramTimepoint: at Baseline & 60th day.

Countries

India

Contacts

Public ContactMohd Muzammil Mohd Ibrahim

National Institute of Unani Medicine

kzarnigar15@gmail.com7483244027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026